HSBC Raises Price Target for Merck & Co to $172.00

HSBC analysts have increased their price target for Merck & Co (MRK) to $172.00, a 14.67% rise from the previous target of $150.00. This positive sentiment comes amidst a series of favorable ratings from various analysts.

The company's robust product pipeline and market position are major contributors to the increased confidence in its future performance. Merck & Co operates within the healthcare sector, specifically within the drug manufacturing industry, with a market capitalization of approximately $361.9 billion.

However, GuruFocus' GF Value calculation indicates that MRK is currently trading at a 22.2% premium compared to its intrinsic value, suggesting that investors might be paying more than what the company is fundamentally worth.